Akademik Veri Yönetim Sistemi
TÜBİTAK - AB COST Projesi , 2022 - 2026
Pancreatic cancer (PC) has a high mortality rate and is
projected to become a massive public health problem in Europe. This Action will
boost research on prevention of PC, particularly in the discovery of genetic
risk factors, risk stratification, identification of biomarkers for early
detection and patient monitoring, elucidation of biological mechanisms and
functional pharmacogenomics for personalized medicine. These aims will be
attained by expanding an existing interdisciplinary network. The Action will be
organized in the following working groups: Disease risk profiling. This WG will
use germline genetic variants, epigenetics, transcriptomics and environmental
factors to model disease risk and apply risk stratification scores to better
select individuals eligible to be screened for PC or its precursors.
Non-invasive biomarkers. This WG will apply state-of-the-art liquid biopsies
for the detection and characterization of circulating tumor cells and DNA, tumor-derived
exosomes, tumor-educated platelets, epigenetic markers, and will test their
diagnostic value for PC precursors and early-stage PC. Tumor profiling.
Genomic, epigenomic and transcriptional profiling of PC and its precursors in a
multiregional analysis fashion will be used to identify novel biomarkers with
prognosis and predictive value for PC patient stratification. Functional
genomics and therapy. This WG will functionally validate candidate genetic
variants from germline or tumor studies by using cutting-edge approaches such
as CRISPR-Cas9 gene editing. It will also generate novel approaches such as
organoids / zebrafish avatars to implement (chemo)therapeutic strategies based
on the patient in an effort to implement personalized medicine for PC.